rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Artivion, Inc.

AORT · NYSE

Health CareMedical DevicesNot moving yet

AORT stood above a rising 150-day average in 14 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 19.8% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 38
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$29.2M
Officials’ trades on record
11
Institutions holding
191 (-27)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$8.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

11 disclosed lines: House 5, Senate 3, executive 3; 4 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k20 Aug 2026filed 10 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k29 Jul 2026filed 22 Sep 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k16 Jul 2026filed 4 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k4 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k15 May 2026filed 1 Jul 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k9 Oct 2025filed 18 Nov 2025
Tina Smith Senate: U.S. Senate eFDSenatorboughtspouse$50k–$100k16 Nov 2023filed 20 Nov 2023
Tina Smith Senate: U.S. Senate eFDSenatorboughtspouse$50k–$100k10 Nov 2023filed 20 Nov 2023
Josh Gottheimer House: U.S. House ClerkNJ05boughtjoint$1k–$15k14 Jul 2023filed 21 Aug 2023
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k13 Jun 2023filed 11 Jul 2023
Tina Smith Senate: U.S. Senate eFDSenatorboughtspouse$50k–$100k23 Sep 2022filed 17 Oct 2022

Insiders

Buy orders, 12 months0
Sale orders, 12 months57
Buyers · sellers0 · 8
WhoDidSharesTraded
Andrew M. GreenSVP, Regulatory and Qualitysold11,480at $24.9710 Sep 2026filed 11 Sep 2026
Andrew M. GreenSVP, Regulatory and Qualitysold1,493at $26.023 Sep 2026filed 4 Sep 2026
Andrew M. GreenSVP, Regulatory and Qualitysold6,510at $27.272 Sep 2026filed 4 Sep 2026
James P. MackinPresident & CEOsold70,000at $28.9619 Aug 2026filed 20 Aug 2026
Lance A. BerryEVP, COO, CFO & Treasurersold715at $28.5514 Aug 2026filed 17 Aug 2026
Andrew M. GreenSVP, Regulatory and Qualitysold616at $28.5514 Aug 2026filed 17 Aug 2026
Jean F. HollowaySVP, General Counselsold977at $28.4912 Aug 2026filed 12 Aug 2026
Andrew M. GreenSVP, Regulatory and Qualitysold14,001at $20.7111 Jun 2026filed 15 Jun 2026
Andrew M. GreenSVP, Regulatory and Qualitysold30,000at $20.6911 Jun 2026filed 15 Jun 2026
Jean F. HollowaySVP, General Counselsold8,962at $38.004 Mar 2026filed 4 Mar 2026
James P. MackinPresident & CEOsold17,887at $37.783 Mar 2026filed 4 Mar 2026
Lance A. BerryEVP, COO, CFO & Treasurersold6,316at $37.783 Mar 2026filed 4 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders191-27 on the quarter
New · exited39 · 66
Reported value$1.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20266,674,017$150.0M+199,163+3.1%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.added · filed 14 Aug 20263,184,974$71.6M+728,828+29.7%
MORGAN STANLEYadded · filed 13 Aug 20262,557,961$57.5M+288,667+12.7%
Juniper Investment Company, LLCadded · filed 14 Aug 20262,019,885$45.4M+830,749+69.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,004,619$45.0M+52,611+2.7%
FMR LLCreduced · filed 13 Aug 20261,963,471$44.1M-619,956−24.0%
STATE STREET CORPadded · filed 7 Aug 20261,858,051$41.8M+175,778+10.4%
Ophir Asset Management Pty Ltdadded · filed 14 Aug 20261,800,008$40.4M+849,158+89.3%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 20261,737,290$39.0M+100,000+6.1%
Conestoga Capital Advisors, LLCadded · filed 24 Jul 20261,623,700$36.5M+448,290+38.1%
31 Mar 2023 – 30 Jun 2026
109164218Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Andrew M. Green Company insiderSVP, Regulatory and Quality · last 10 Sep 20260 · 16
Gilbert Ray Cisneros, Jr. HouseCA31 · last 20 Aug 20262 · 1
James P. Mackin Company insiderPresident & CEO · last 19 Aug 20264 · 34
Lance A. Berry Company insiderEVP, COO, CFO & Treasurer · last 14 Aug 20260 · 7
Jean F. Holloway Company insiderSVP, General Counsel · last 12 Aug 20260 · 47
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20260 · 3
Anthony B. Semedo Company insiderDirector · last 2 Jun 20262 · 3
Daniel J. Bevevino Company insiderDirector · last 18 May 20260 · 1
Elizabeth A. Hoff Company insiderDirector · last 18 May 20260 · 1
James Bullock Company insiderDirector · last 18 May 20261 · 0
Jeffrey H. Burbank Company insiderDirector · last 18 May 20260 · 0
Jon W. Salveson Company insiderDirector · last 18 May 20261 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202564.4%
Operating profit marginFY 2025 · to 31 Dec 20257.6%
Free cash flow marginFY 2025 · to 31 Dec 20250.2%
Return on capital employedFY 2025 · to 31 Dec 20254.3%
Cash conversionFY 2025 · to 31 Dec 2025408%
Debt to equityFY 2025 · to 31 Dec 20250.48×
Research spendFY 2025 · to 31 Dec 20257.0%
Share count trendFY 2025 · to 13 Feb 20261.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$64.9M
Free cash flowFY 2025 · to 31 Dec 2025$839K

Analyst forecasts

No analyst forecasts yet.